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Comparative Effectiveness — Thinking Beyond Medication A versus Medication B
Abstract
The American Recovery and Reinvestment Act of 2009 (ARRA), the stimulus package signed into law by
President Barack Obama on February 17, 2009, directs $1.1 billion to support “the development and
dissemination of research assessing the comparative effectiveness of health care treatments and
strategies, including through efforts that . . . conduct, support, or synthesize research that compares the
clinical outcomes, effectiveness, and appropriateness of items, services, and procedures that are used to
prevent, diagnose, or treat diseases, disorders, and other health conditions.”
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Comparative Effectiveness — Thinking beyond Medication A
versus Medication B
Kevin G. Volpp, M.D., Ph.D., and Anup Das

T

he American Recovery and
Reinvestment Act of 2009
(ARRA), the stimulus package
signed into law by President
Barack Obama on February 17,
2009, directs $1.1 billion to support “the development and dissemination of research assessing
the comparative effectiveness of
health care treatments and strategies, including through efforts
that . . . conduct, support, or
synthesize research that compares the clinical outcomes, effectiveness, and appropriateness of
items, services, and procedures
that are used to prevent, diagnose,
or treat diseases, disorders, and
other health conditions.”
The rationale for seeking better information on comparative
effectiveness is well understood.
Many existing devices and therapeutic approaches have never been
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subjected to the scrutiny of randomized, controlled trials comparing them with placebos, and
even fewer have been directly
tested against other approaches
to improving the health of people
with a given condition. Though
there is controversy over whether
such evaluations should include
information on cost-effectiveness
and how the findings should be
used in coverage decisions, there
is little debate that both health
care professionals and the public will benefit greatly from better data to inform their choices
among the available therapies for
a given condition.
In considering the allocation
of federal resources for comparative-effectiveness research (CER),
however, it is important that we
maintain a broad view of ways of
improving the health of the population. As many as 40% of premature deaths in the United States
are attributable to Americans’ own
health-related behaviors. If CER’s
full potential for improving the
population’s health is to be realized, such comparisons must go
beyond those between medication
A and medication B or device A
and device B: we must also assess
medications or devices in comparison with behavioral interventions,
either alone or in conjunction
with other approaches. In addition, since many diverse aspects
of care delivery have a direct effect
on patients’ health outcomes, we
should assess policy-based inter
ventions and their relative effectiveness in improving health.

In many cases, it seems clear
that patients’ individual healthrelated behaviors are the proximate cause of disease and of the
need for medical treatments. For
example, obesity is a major risk
factor for hypertension, diabetes,
lower back pain, and other conditions. Patients who are able to
lose weight may be able to reduce or eliminate their use of
medications for these conditions.
It therefore makes sense to compare, among patients with diabetes, medication-based approaches
to the treatment of diabetes with,
for example, the effects of behavioral approaches to weight
reduction.
One of the best-known randomized, controlled trials comparing a lifestyle intervention with
medical therapy, the Diabetes Prevention Program, showed that
over a mean follow-up period of
2.8 years, intensive lifestyle therapy was significantly more effective than metformin therapy in
preventing the onset of diabetes
among persons without diabetes
who, at enrollment, had elevated
fasting and elevated post-load
plasma glucose levels.1 The incidence of diabetes was 11.0, 7.8,
and 4.8 cases per 100 personyears in the placebo, metformin,
and lifestyle-intervention groups,
respectively, meaning that the
lifestyle intervention reduced the
incidence of diabetes by 58% (95%
confidence interval [CI], 48 to 66),
and metformin reduced the incidence by 31% (95% CI, 17 to 43),
as compared with placebo. The
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number of patients who need to
be treated to prevent one case of
diabetes over a 3-year period was
6.9 with the lifestyle-intervention program and 13.9 with metformin.
Through our own research,
we have found that financial incentives for smoking cessation are
highly effective, tripling smokingcessation rates at 9 to 12 months
and resulting in “quit rates” that
are 2.6 times those achieved with
a control treatment at 15 to 18
months, 6 months after the termination of the incentive pro
gram.2 To illustrate the importance of comparing behavioral
therapies with “standard therapy”
for smoking cessation, we compared our results with those published in three recent meta-analyses of placebo-controlled trials of
medical therapies for smoking
cessation, such as Zyban (bupropion), Chantix (varenicline), and
nicotine-replacement therapies
(gum, patches, spray, lozenges,
and inhalers).3-5 We were interested in how the benefits of pharmacologic therapies compared with
those of financial incentives in
terms of the pooled odds ratios
for 12 months of continuous abstinence (see graph).
This example highlights the
value of including behavioral approaches in comparative studies:
incentives appear to be at least
as effective as pharmacologic aids
in helping smokers to achieve
long-term abstinence. Incentives
may also be more cost-effective
than medications, since they are
paid only to smokers who succeed in quitting, whereas many
patients who take medications for
smoking cessation are unsuccessful. Such a comparison, however,
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is no substitute for trials directly
comparing the effectiveness of
treatments. Different studies may
have different quit rates because
of the composition of the study
population. We focused on the
ratio of the quit rates in the treatment group and the control group
in each study rather than directly
comparing the quit rates between
studies. The effectiveness of a given treatment may also vary with
the population being studied,
and direct, head-to-head comparisons of different approaches are
needed.
On the population level, the
behavior of the health care delivery system itself is another important factor in health outcomes
whose effects are not captured
in traditional CER. For instance,
the recently released report by the
Institute of Medicine on residents’
duty hours and patients’ safety
(Resident Duty Hours: Enhancing Sleep,
Supervision, and Safety) highlighted
a number of policy interventions
that are believed to affect patients’ outcomes. Such interventions are rarely subjected to the
same level of scrutiny as medical treatments, though variations
in certain aspects of care delivery — such as use of electronic
medical records, weekend and
overnight staffing, and the work
intensity of health care providers,
their cross-coverage patterns, and
the numbers of continuous hours
and hours per week that they
work — can have a tremendous
effect on patients’ safety. If the
CER initiative is intended to improve the health of populations,
some portion of the research efforts should focus on the relative
effectiveness of system-level chang
es in improving outcomes for a
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population of patients. Such efforts could include hospital-based,
regional, or national quality-
improvement interventions; behavioral economic interventions,
such as changing default options
(e.g., automatically providing 90day, rather than 30-day, refills
of prescriptions for chronic conditions); efforts using incentives
to steer patients toward shortterm decisions that are in their
long-term best interest; and various regulatory, policy, or legislative approaches.
Several examples highlight the
power that such approaches may
have in achieving changes in
health outcomes. For example, the
scarcity of organs for transplantation could be addressed through
an “opt-out” approach similar to
those used by many Western European countries; countries in which
an “opt-out” approach is used
typically have organ-donation
rates above 90%, whereas countries with an “opt-in” approach
typically have rates of 5 to 15%,
according to a 2003 study by
Johnson and Goldstein. It is unlikely that any non–policy-based
approach could ever achieve such
an increase in rates. In another
example — to return to smoking
cessation — perhaps the most effective (and probably most costeffective) way to reduce the rate of
smoking, especially among young
people, is to raise excise taxes.
In general, CER is a public
good that has the potential to
greatly inform the decisions of individual clinicians, patients, policy
makers, and insurance plans in
guiding the American people to
preferentially use more-effective
treatments. The full potential of
this effort will be realized only if
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we define problems broadly and
include in these comparisons
rigorous testing of behavioral
and policy-based approaches to
improving the health of populations.
Dr. Volpp reports receiving consulting fees
from McKinsey, lecture fees from Aetna, and
grant support from Pfizer. No other potential
conflict of interest relevant to this article
was reported.
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Health Care 2009: Health Care Reform Center
To follow the evolving U.S. health care reform story, visit our Health Care Reform Center at
healthcarereform.NEJM.org, a new source for health care policy news, opinion, and commentary.

n engl j med 361;4

nejm.org

july 23, 2009

The New England Journal of Medicine
Downloaded from nejm.org at UNIV OF PENN LIBRARY on July 18, 2017. For personal use only. No other uses without permission.
Copyright © 2009 Massachusetts Medical Society. All rights reserved.

333

